Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. [electronic resource]
Producer: 20090406Description: 242-8 p. digitalISSN:- 1523-6536
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Female
- Fluorodeoxyglucose F18
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, B-Cell -- diagnosis
- Lymphoma, Non-Hodgkin -- diagnosis
- Male
- Middle Aged
- Platinum Compounds -- therapeutic use
- Positron-Emission Tomography
- Prognosis
- Risk Assessment
- Salvage Therapy -- methods
- Survival Analysis
- Transplantation, Autologous
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.